Greater Cannabis Company (GCAN) Interest & Investment Income (2018 - 2019)
Greater Cannabis Company's (GCAN) quarterly Interest & Investment Income came in at -$3972.0 in Q3 2019, up 72.64% year-on-year from -$2300.8 in Q3 2018, and up 72.64% quarter-over-quarter from -$14515.0 in Q3 2018.
Greater Cannabis Company (GCAN) Interest & Investment Income (2018 - 2019) Analysis & Trends
Greater Cannabis Company's Interest & Investment Income history runs 2 years deep, the most recent figure standing at -$3972.0 for Q3 2019.
- On a quarterly basis, Interest & Investment Income rose 72.64% year-over-year to -$3972.0 in Q3 2019; TTM through Sep 2019 was -$18487.0, a N/A change from a year earlier, with the FY2018 full-year figure at $5903.0, changed N/A from the prior year.
- Interest & Investment Income climbed to -$3972.0 in Q3 2019 per GCAN's latest filing, from -$14515.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $5903.0 in Q1 2018 and bottomed at -$14515.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Greater Cannabis Company | 255,226.94 | 255,226.94 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | -3,972.00 |
| Sep 30, 2018 | -14,515.00 |
| Mar 31, 2018 | 5,903.00 |